Search Results
Age-stratified findings from the monarchE trial of abemaciclib in breast cancer
4-year MonarchE results: increasing benefits with abemaciclib + ET for ER+/HER2- high-risk early BC
MonarchE 4-year: abemaciclib + endocrine therapy for HR+, HER2-, node-positive, high-risk early BC
MonarchE results: Abemaciclib plus endocrine therapy in high-risk early breast cancer
monarchE: adjuvant abemaciclib in HR+ breast cancer
MonarchE: investigating adjuvant abemacicilib for high-risk HR+ breast cancer
Safety outcomes in the Phase III monarchE trial of abemaciclib + ET in HR+, HER2- breast cancer
monarchE: adjuvant abemaciclib + endocrine therapy in patients with HR+, HER2- high-risk eBC
MonarchE Trial
Abemaciclib for HR+/HER2- advanced or metastatic breast cancer
Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim data
Adjuvant Abemaciclib/Ribociclib #monarchE/NATALEE #Best Treatment for Breast cancer #CDK 4/6 -Cure